Recent Finacing
Recent Raise
Disc Medicine develops hepcidin‑targeted therapies for hematologic diseases, advancing oral small molecules and anti‑hemojuvelin monoclonal antibodies to restore red blood cell production.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Disc Medicine.
